Uppsala, Sweden, April 25, 2025. Resitu, a Swedish company developing pioneering devices for full excision of breast tumors, has appointed Åsa Runnäs as the company’s CEO, building on her 20 years of experience in device regulation and commercialization. Åsa Runnäs is one of Resitu’s core investors, part of its founding team, and has served […]
The post Resitu Strengthens C-Suite With New CEO as it Prepares for Commercialization of its Breast Tumor Removal Device first appeared on Business News Week.